IL2 and neoplasm: Preclinical observations strongly support the potential anti-tumour activity of IL-15 mediated by NK cells and T lymphocytes.41,42 Unlike IL-2, IL-15 does not stimulate Treg cells, a subset that might reduce the anti-tumour activity of NK and T cells.